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Abstract
Background: Mutations of the amyloid precursor protein gene (APP) are found in familial forms of Alzheimer’s disease (AD)
and some lead to the elevated production of amyloid-b-protein (Ab). While Ab has been implicated in the causation of AD,
the exact role played by Ab and its APP precursor are still unclear.
Principal Findings: In our study, Drosophila melanogaster transgenics were established as a model to analyze AD-like
pathology caused by APP overexpression. We demonstrated that age related changes in the levels and pattern of synaptic
proteins accompanied progressive neurodegeneration and impairment of cognitive functions in APP transgenic flies, but
that these changes may be independent from the generation of Ab. Using novel peptide mimetics of Apolipoprotein-E,
COG112 or COG133 proved to be neuroprotective and significantly improved the learning and memory of APP transgenic
flies.
Conclusions: The development of neurodegeneration and cognitive deficits was corrected by injections of COG112 or
COG133, novel mimetics of apolipoprotein-E (apoE) with neuroprotective activities.
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Introduction
Alzheimer’s disease (AD) represents the most common neuro-
degenerative disease occurring in mid-to-late life [1]. Clinically,
AD manifests as a gradual decline of cognitive functions such as
learning and memory, which significantly correlates with synaptic
loss [2–4]. The mechanism(s) by which synaptic dysfunction occurs
is not well understood. However, numerous results show that
synaptic dysfunction occurs in the very early stages of many
neurodegenerative diseases and precedes accumulation of abber-
ant protein aggregates [5–8]. Furthermore, studies with transgenic
animals recapitulated very similar early pathologic events for
different disease models [9–12].
Animal models of AD typically mimic the pathogenesis of early
onset familial AD that are caused by mutations in the amyloid
precursor protein (APP) and presenilin (PS1 and PS2) genes [13].
APP is a large, type I transmembrane protein, which is cleaved by
different membrane associated proteases known as a, b and
c-secretases [14]. The coordinated action of b– and c–secretases
result in the formation of a 40–42 amino acid peptide named as
amyloid beta protein (Ab) whose beta pleated sheet conformation
is a main constituent of amyloid plaques in AD brain [15]. In
contrast, a -secretase cleaves APP in the middle of the Ab region
and prevents its production [14]. Additionally, it has been shown
that PS1 is an integral part of the c-secretase protease consisting of
at least four different proteins in a membrane associated complex
[16].
In most animal models of AD, overexpression of APP, with or
without mutated presenilin expression, yields elevated levels of Ab
production and accumulation of oligomeric Ab species that may
contribute to synaptic failure and cognitive deficits [4].
Although APP overexpression and Ab deposition in transgenic
animals do not faithfully recapitulate all aspects of AD, they offer
real opportunities for studying AD related neuropathology. In
particular, these animal models help to explain the contributions
of APP and Ab in familial AD pathogenesis. In this respect,
transgenic Drosophila models have several advantages for investi-
gation of AD pathology. First, the Drosophila APP homologue, an
APP-like protein (APPL) lacks the Ab peptide region and its
processing does not lead to neurotoxic effects [17]. Second,
because b-secretase (BACE) activity is not present in Drosophila
[18–20], APP expression in transgenic flies allows one to
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and secreted Ab. More importantly, transgenic Drosophila can be
used to better understand targets for protective treatments to
preserve cognitive and functional abilities in AD patients.
We now report that overexpression of human APP in neural
cells of Drosophila leads to synaptic dysfunction, neurodegeneration,
Ab secretion and Ab aggregation in the fly brain. Novel
neuroprotectors, known as mimetics of apolipoprotein E (apoE),
block neurodegeneration and restore cognitive functions in
transgenic Drosophila. Selection of apoE-mimetics derived from
the receptor-binding region of apoE was based on the ability of
these peptides to mimic the functional anti-inflammatory and
neuroprotective effects of the intact apoE protein seen in different
animal models of neurological diseases [21,22]. Moreover, these
peptides suppressed elevation of Ab1-42 levels in mice after head
injury [23]. In summary, apoE mimetics are useful tools to mark
the functional connections between neurodegeneration, cognitive
impairment, Ab secretion and Ab aggregation
Results
I. Modeling AD Neuropathology in Drosophila
APP expression and accumulation of Ab in transgenic fly
brain. To express human APP genes in neuronal cells of
Drosophila, we used the UAS/Gal 4 system [24]. In this system, the
yeast transcriptional activator Gal 4 directs transcription of the
transgene, which has been placed under the transcriptional control
of an Upstream Activating Sequence (UAS). Flies carrying the
UAS-APP transgene, in which a human APP cDNA was located
downstream of the UAS promoter, were crossed to flies carrying a
Gal 4 (elav-GAL4
c155) transgene, which expresses predominantly in
neurons [25]. Transgenes with the elav;APP genotype express APP
at levels higher than the endogenous APPL gene [20,26]. In UAS-
APP-expressing lines, antibodies against the N-terminal region of
human APP (22C11) detected full-length forms of APP695
[Fig. 1A-22C11(APP-N), elav; APP]. Double transgenic lines
coexpressing human APP and BACE resulted in the partial loss
of the larger APP band [Fig. 1A-22C11(APP-N), elav; APP/BACE].
Immunoprecipitation of SDS-protein extracts from the heads of
elav; APP/BACE transgenics with monoclonal antibody 4G8
revealed Ab monomer and SDS-stable Ab oligomers [Fig. 1A-
4G8(IP), elav APP/BACE]. Ab derived from human APP
expression was detectable in immunoprecipitates at 2 days after
eclosion. We did not detect Ab monomer and Ab oligomers in
immunoprecipitates of flies with the elav; APP genotype, where
staining was detected only at the top of gradient gel reflecting the
position of IgG migration. Immunohistochemistry demonstrated
that Ab deposits in the Drosophila brain were detected mainly in the
outer cellular cortex layer that contains neuronal and glial cells in
flies simultaneously expressing APP and BACE [Fig. 1B-b,d; elav;
APP/BACE].
Distribution of GFP–n-synaptobrevin in the transgenic
Drosophila brain. Next, we studied distribution of n-
synaptobrevin in brain sections of transgenic Drosophila.
Synaptobrevin is one of the main presynaptic proteins and
represents a reversible linker between synaptic vesicles and the
cytoskeletal meshwork. Thus, the distribution of n-synaptobrevin
in neural cells of Drosophila brain may demonstrate cytoskeletal
integrity and illuminate possible abnormalities in synaptic
functions. We used green fluorescent protein (GFP) fused in
frame with n-synaptobrevin (n-syb-eGFP) as a detection reporter
for its local distribution. Several transgenic lines were studied
including flies expressing APP, APP-Swedish and N- or C–
terminally truncated APPs. APP–Swedish is an APP695 transgene
with the (670K3N, 671M3L) mutations found in familial AD [13].
The gene encoding APPDCT included sequences for the
extracellular domain, Ab, and the short membrane anchor
KKKR, followed by a stop codon [27]. The APPDNT structure
included the sequence of the APP signal peptide fused with an
APP695 C-terminal fragment beginning from the residue N584
located at a distance of 12 amino acid residues upstream from the
59-site of BACE cleavage [27]. Thus, DNT also included the Ab
sequence. The presence of the Ab domain in all truncated APP
forms studied here was necessary for axonal transport of the
truncated APP to the presynaptic terminal [28].
Laser confocal microscopy in transgenic lines expressing n-syb-
eGFP showed that fluorescence is largely localized in the
mushroom bodies, the brain region involved in associative learning
Figure 1. Human APP expression in the brain of transgenic
Drosophila.A ) Western blot analysis of APP and Ab: 22C11 (APP-N): Full
size human APP was detected by monoclonal antibody 22C11 (APP N
terminal-specific); 4G8 (IP): Ab was immunoprecipitated using anti-Ab
monoclonal 4G8 antibody; elav;APP; and -elav;APP/BACE- genotypes of
transgenic strains used for analysis. All blots were scanned and relative
intensity of bands was quantified using Image J software. B)A b
deposits in Drosophila brain: 4G8 (IH): Immunohistochemistry with 4G8
antibody; Arrows indicate areas for magnification. Bar, 50 mm (a, b); Bar,
10 mm (c, d).
doi:10.1371/journal.pone.0008191.g001
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is responsible for olfactory function [Fig. 2A]. A significant
reduction in fluorescence intensity in mushroom bodies and
antennal lobes was seen in transgenics expressing full size APPs
and n-syb-eGFP in 30-day-old flies. The most significant reduction
of fluorescence intensity in optical slices was detected in
transgenics expressing APP-Swedish plus BACE. In contrast,
reduction of n-syb-eGFP levels in flies expressing truncated APPs
was not significant in 30-day old flies compared with those
expressing n-syb-eGFP alone [Fig. 2A]. As an additional control,
signal intensities of n-syb-eGFP in the mushroom bodies and in the
antennal lobes were almost equal in all transgenic lines on the
second day after hatching (data not shown). For calculation of
relative intensities, all pixel intensities in the selected areas were
normalized to the fluorescent signal/pixel intensities of the elav
genotype. Relative intensities are shown as mean6SEM. Quan-
titation of n-syb-eGFP fluorescence demonstrates the following:
first, transgenics expressing APP plus BACE had lower levels of
presynaptic proteins than transgenics expressing only APP and
second, overexpression of full length APP may be sufficient for
abnormal synaptogenesis in the Drosophila brain.
Age-dependent neurodegeneration in transgenic Droso-
phila. The age-related change in the pattern of n-syb-eGFP
fluorescence in Drosophila expressing APP was accompanied by
progressive neurodegeneration. Vacuolization of neuronal tissues
is the major hallmark of neurodegeneration in flies [29]. As seen in
Fig. 3, all APP transgenics demonstrate vacuolar lesions, which are
progressive from days 1 to 30. We did not observe vacuolar lesions
associated with neurodegeneration in the brains of any transgenic
Drosophila line on the first day after hatching. On the 15th day,
small vacuolar foci appeared in the neuropil and the number of
the foci continued to increase with time until day 30. Vacuoles
were mostly located in the neuropil while the optic lobes were less
affected (Fig. 3). Although the number of vacuoles varied from
sample to sample, we did not find significant differences between
transgenics that expressed BACE and those that lacked BACE. All
genotypes revealed strong neurodegeneration in comparison with
controls (elav) [Fig. 3B].
Age-dependent learning and memory defects in
transgenic flies. All transgenic Drosophila lines expressing
full length APPs showed reduced learning and memory when
tested using an olfactory learning assay [30]. Briefly, 50–100
flies from each line were sequestered in a closed chamber and
trained by exposing them sequentially to two odors (octanol or
methylcyclohexanol). Flies received electric shock pulses in the
presence of the first odor, but not in the presence of the second
odor. Trained flies were then tested for conditioned avoidance
responses. Immediately after training, learning was measured
by allowing flies to choose between the two odors for 120
seconds (Learning Index) or after 1.5 hours (Memory index).
The Learning Index and Memory Index for different genotypes
are summarized in Tables 1 and 2. In general, a significant
decline in learning and memory was observed for all lines
expressing full length APPs in neuronal cells. This decline was
detected in 1- to 2-day-old flies and became more pronounced
as the flies aged.
Figure 2. Distribution of GFP–n-synaptobrevin in the Drosophila brain. A) Optical sections of the brain obtained by confocal microscopy
(four brightest sections for each genotype). The fluorescent signal was visualized at a wavelength of l 488 nm. The scanning sections were 2 mm
thick. Microphotographs show the brains of 30-day-old flies. B) Quantitation of relative intensities of GFP–n-synaptobrevin (n-syb-eGFP) in the brain
section for transgenic flies with different genotypes: 1.-elav; 2- elav;DNAPP; 3- elav;DCAPP; 4-elav;APP; 5-elav;APPSw; 6-elav;APP/BACE; 7- elav;
APPSw/BACE. The pixel intensity in the selected areas was estimated using Image J software and was normalized to the fluorescent signal of elav
genotype. Relative intensities are shown as averages6SEM. p,0.05.
doi:10.1371/journal.pone.0008191.g002
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In vivo delivery of peptides into brain cells. ApoE-
mimetic peptides are well known to display anti-inflammatory and
neuroprotective effects in the central nervous system [21,22].
Therefore, we tested whether the apoE-mimetic peptides could
modify neurodegeneration, amyloidogenesis and cognitive
functions in transgenic Drosophila models of AD. With the aim of
enabling efficient intracellular delivery of apoE-mimetics, we
employed protein transduction domain (PTD) technology and
evaluated the ability of one of the PTD peptides, penetratin (a 16-
amino acid peptide derived from the Drosophila Antennapedia
homeodomain protein, Antp) to carry a cargo (apoE peptide-
COG133) into brain cells. Both penetratin and COG133 crossed
the blood brain barrier (BBB) in rodents [21,31]. However, fusion
of Antp to COG133 resulted in significantly enhanced therapeutic
effects in animal models [31,32]. To analyze, whether this fusion
peptide is capable of crossing the BBB in Drosophila, we injected
Antp-COG133 (known as COG112) peripherally into the
abdomen, which is filled with the hemolymph that bathes all
outer surfaces of the fly brain. To discriminate whether peptide
actually crossed the BBB or was simply trapped within the thin
layer of perineurial and glial cells, we used microscopy to detect
biotin-tagged peptide on whole slices in the parenchymal regions
of the brain structures. As seen in Fig. 4, intensity of staining was
much higher in the outer cellular cortex layer containing neuronal
and glial cells when compared with neuropil areas. However, at
this level of resolution, it is difficult to conclude whether the biotin-
tagged peptide penetrated inside specific brain cells. Experiments
without added peptides or with injected control peptide CF, which
does not cross BBB [33], demonstrated only very weak staining.
Effect of peptides on neurodegeneration. The develop-
ment of vacuolar defects was almost entirely ameliorated by
injections of COG112 or COG133 in elav;APP/BACE and
elav;BACE;APP-Sw transgenic lines [Fig. 5]. Amounts of different
sized vacuoles in the neuropil of the central brain and optical lobes
were drastically decreased after seven injections of apoE peptides.
The protective effect was significant even on day 15–17 day
following the fourth injection of peptides. In control experiments,
injections of penetratin (Antp) in the same doses did not block
neurodegeneration. Six brains for each genotype and 16–18
sections per brain were analyzed. Significant differences from
controls (p,0.05) were observed for COG112 and COG133 for
both tested genotypes (elav;APP/BACE and elav;BACE;APP-Sw).
Effect of peptides on learning and memory. To clarify
whether apoE-mimetics could inhibit vacuolarization associated
with neurodegeneration and help to restore cognitive functions, we
analyzed the effects of COG112 or COG133 on learning and
memory in two APP expressing lines: elav;APP/BACE and
elav;BACE/APP-Sw. These lines showed the strong vacuolarization
associated with neurodegeneration and a reduction of synaptic
protein levels in mushroom bodies, centers for olfactory learning
and memory. After two injections over the first 7 to 8-days of age,
COG112 or COG133 treatments did not show any effects on
Table 1. Progressive loss of learning ability in APP-transgenic flies.
Age of animal Genotype 1–2 days 7–8 days 13–14 days 21–22 days 28–30 days
elav-GAL4
c155*6 1 . 2 65.2 6.863.6 38.664.6 34.262.8 31.266.7
UAS-APP*5 8 . 4 64.7 57.066.3 52.765.8 44.864.4 37.467.1
UAS-APP-Sw*5 5 . 4 64.3 42.563.0 33.363.6 33.762.6 35.365.3
elav;APP 9.864.1 9.664.3 3.662.3 2.561.5 2.061.9
elav;APP/BACE 13.664.0 9.362.9 6.461.8 5.361.2 3.762.1
elav;APP-Sw 22.462.4 15.364.8 11.664.1 4.962.8 4.062.3
elav;BACE;APP-Sw 28.064.2 19.363.7 13.863.7 8.263.0 4.261.8
The Learning Index was calculated as described in ‘‘Materials and Methods’’. All scores are expressed as mean6SEM, (n=6) where (n) is the number of independent
assays. Asterisk (*) indicates control transgenic lines. Statistical analysis was performed using one-way ANOVA and Tukey-Kramer multiple comparison post hoc test.
Significance was accepted at p,0.05.
Groups of flies showing statistically significant differences from controls in learning index are shown in bold font.
doi:10.1371/journal.pone.0008191.t001
Figure 3. Age-dependent neurodegeneration in APP expressing
transgenics. Microphotographs of the brains of 30-day-old flies; Bar,
50 mm. A) Percentage of the area lost in the regions of the cell body
and neuropil: The ratio of lost area was calculated by dividing the sum
of the vacuole areas from all brain sections by the total area of the brain
from all brain sections. We analyzed 6 brains for each genotype, 16–18
sections per brain. Percentage of the area lost is shown as
averages6SEM. p,0.05. B) Neurodegeneration in APP flies at day 30.
Paraffin slices were stained with hematoxylin and eosin and were
examined under bright-field illumination using a Leica DM 2500
microscope at a magnification of 120X.
doi:10.1371/journal.pone.0008191.g003
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additional treatments of COG112 or COG133, however,
significant positive effects on restoring learning and memory
abilities were observed for COG112 and for COG133 by days
21–22 of age. For the elav;BACE; APP-Sw genotype that displayed
severe vacuolarization and decreased levels of synaptic proteins,
statistically significant restoration of memory was only detected with
COG133 in 7-8-day-old flies. These effects of apoE-peptides on
learning and memory are summarized in Table 3.
Effect of peptides on Ab deposition. Although our results
show that apoE-mimetics appear to restore cognitive functions in
APP transgenic flies, we did not know if this effect resulted from
interfering with Ab pathology. To address this point, we
investigated the effects of COG112 on Ab accumulation in
Drosophila brain. We analyzed the effect of oral administration of
COG112 (aka. Antp-COG133) to an APP transgenic line with the
elav;APP/BACE genotype. This line has been characterized by a
high level of Ab deposits accompanied by strong age-related
neurodegeneration and a significant reduction in the levels of
synaptic proteins. We chose to test COG112 because previous
experiments showed that COG112 was more efficiently delivered
into cells and it was more stable in experiments in vivo [32]. Flies
were cultured on standard fly food containing tested peptides,
which were added every day at concentrations: 11.47 mM
COG112, 11.71 mM Antp, or 3.72 mM Antp-SH8. SH8-
represented a previously tested inhibitor of Ab aggregation [34].
As seen in Fig. 6A, significant Ab deposition in the Drosophila brain
was detected in the cortical layer containing neurons. Much less
Ab deposition was detected in the neuropil. Oral administration of
Antp-SH8 remarkably decreased the size and density of Ab-
positive deposits. Antp alone did not appear to change Ab
accumulation in the brain (Fig. 6B). Several brain samples showed
decreased size of Ab deposits after COG112 administration, but
the effect of this peptide is difficult to evaluate due to significant
variations in detectable Ab deposits. Most likely these results
suggest a slight effect of this peptide on Ab levels, which will
require more refined methodologies to precisely measure.
Functional integrity of peptides during oral administration was
tested by comparison of their effects on neurodegeneration with
effects of the same peptides after abdominal injections. COG112,
COG133 and Antp-SH8 all inhibited neurodegeneration to an
equal degree that was independent of the method of peptide
delivery, while Antp alone had no effect (Table 4).
Discussion
A large number of studies implicated defective processing of
APP and formation of neurotoxic Ab oligomers as a main cause of
synaptic dysfunction in AD [4,35]. However, the idea that only
enhanced production of Ab oligomers may lead to neurodegen-
eration and synaptic dysfunction has been challenged by recent
results, suggesting that impaired functions of PS1, PS2 and/or
APP may contribute to AD-like synaptic pathology in a fashion
that is independent from Ab generation. Indeed, conditional PS1
and PS2 knockout mice have been characterized by classical
hallmarks of AD neuropathology including tau hyperphosphoryla-
tion, progressive neurodegeneration, impairment of synaptic
plasticity and memory loss, all in the absence of Ab [36,37]. In
parallel, deficits in synaptic plasticity and cognitive functions were
detected in APP knockout or APP knockdown animal models
[38,39]. These results suggest that the presence or absence of APP,
independent of Ab, may lead to some form of synaptic pathology
and dysfunction.
Several studies using transgenic Drosophila were directed to
discriminate effects of exogenous APP and Ab. Transgenic flies
Table 2. Progressive loss of memory in APP-transgenic-flies.
Age of animal Genotype 1–2 days 7–8 days 13–14 days 21–22 days 28–30 days
elav-GAL4
c155*5 7 . 9 63.5 41.562.0 30.262.3 27.661.4 19.762.4
UAS-APP*5 5 . 1 65.1 44.864.1 36.263.6 39.763.6 23.462.7
UAS-APP-Sw*5 3 . 1 65.7 33.263.9 25.063.1 28.763.4 26.363.1
elav;APP 5.063.3 3.962.1 3.061.6 1.260.6 1.060.8
elav;APP/BACE 13.163.3 10.462.2 7.561.5 4.561.7 4.963.2
elav;APP-Sw 9.261.9 7.061.5 7.763.1 7.362.6 5.263.3
elav;BACE;APP-Sw 14.564.8 13.662.5 9.164.2 3.761.8 4.062.5
The Memory Index was calculated as described in ‘‘Materials and Methods’’. All scores expressed as mean6SEM, (n=6) where (n) is the number of independent assays.
Asterisk (*) indicates control transgenic lines. Statistical analysis was performed using one-way ANOVA and Tukey-Kramer multiple comparison post hoc test.
Significance was accepted at p,0.05. Groups of flies showing statistically significant differences from controls in learning index are shown in bold font.
doi:10.1371/journal.pone.0008191.t002
Figure 4. In vivo delivery of peptides into Drosophila brain.
Immunohistochemistry with antibody to biotin: Left panels - Bar,
50 mm; Right panels-Bar, 10 mm. a,b - Antp-COG133 (COG112) -
RQIKIWFQNRRMKWKK LRVRLASHLRKLRKRLL. c,d- CF (fragment 142–
153 of human growth factor U2AF)-SQMTRQARRLYV, control peptide,
which does not cross BBB [33]; e,f – no peptides added.
doi:10.1371/journal.pone.0008191.g004
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amyloid deposits and age-dependent learning defects in olfactory
learning [40]. In other work, flies expressing wild-type Ab-42 and
Arctic mutant Ab-42 (Glu22Gly) showed a decline in climbing
behavior, increased intracellular Ab accumulation and diffuse
plaques prior to signs of neurodegeneration [41]. Recent findings
demonstrated that expression of the Arctic mutant significantly
enhanced formation of Ab oligomers and Ab deposits, together
with a decline of locomotor functions when compared with Ab-art
(artificial mutation L17P) [42]. Surprisingly, different Ab-42
aggregates have distinctive roles in modulation of synaptic
functions. While exogenously prepared small Ab-42 oligomers or
Ab oligomers secreted from neurons lead to a reduction of
neurotransmitter release; larger-sized aggregates, possibly fibrils
secreted by muscle cells, enhanced neurotransmitter release and
synaptic transmission (43).
Because BACE activity is not present in Drosophila, overexpres-
sion of human APP does not lead to secretion of Ab leading to the
interpretation that all phenotypic effects in these transgenic flies
should be attributed to the presence of human APP. Although
APPL processing by endogenous BACE-like enzymes in the fly
could result in accumulation of unusual APPL fragments [44],
transgenics with elav; APP genotypes express human APP at levels
much higher than the endogenous APPL [20,26]. When human
BACE and APP were expressed in combination in fly eyes, diffuse
amyloid plaques and age-dependent neurodegeneration of photo-
receptor cells were observed [20]. Surprisingly, neurodegeneration
was even more pronounced in APP transgenic flies than in APP/
BACE double transgenic flies.
Our data confirm these results whereAPPalone,or APP plus Ab,
may result in different degrees of impairment. We did not find
differences in age-dependent neurodegeneration in transgenic flies
expressing full size APP with BACE or without BACE (Fig. 2).
However,transgenicsexpressingAPPandBACEhad lowerlevelsof
the presynaptic protein GFP-n-synaptobrevin than transgenics
expressing APP alone (Fig. 2B). These findings raise the question
whether the decline of synaptic proteins levels and/or neurodegen-
eration are caused by different mechanisms. Alternatively, we
suggest that Ab represents just a part of a largerpathological process
and independently contributes to different neuropathological
abnormalities caused by APP overexpression. Although the effect
of Ab on reduction of n-syb-eGFP level was readily observable, we
conclude that overexpression offull length APPmaybe sufficientfor
abnormal synaptogenesis in the Drosophila brain. We previously
obtained similar data for another presynaptic protein: GFP-n-
synaptotagmin [45]. Interestingly, only full length APP overexpres-
sion caused a disruption of axonal transport in Drosophila [46].
Most of the described APP transgenic models exhibit learning
and memory deficits that reflect a clinical syndrome associated
with APP pathogenesis [47,48]. In our experiments, we detected
reduced learning and memory in 2 day-old flies, while significant
neurodegeneration and Ab accumulations were observed in 10–15
day-old flies. (Figs. 3 and 6). While the molecular basis for this
finding is not clear, early decline of cognitive functions supports a
primary role for the synaptic dysfunction in these transgenic
models.
A reasonable approach to understand these results is based on
testing compounds that would prevent (or reverse) impairment of
cognitive functions and simultaneously block neurodegeneration,
and/or oligomerization of Ab. We tested the effects of injected
apoE-mimetic peptides with known neuroprotective activity in
different animal models of neurological diseases [22]. A major
obstacle in this approach is the limited penetration of peptides into
the brain. Therefore, we fused the COG133 apoE-peptide with
penetratin to generate COG112 [22], which was previously
successfully tested for the transport of cargo across the BBB in
Drosophila and rodents [31,32,49,50]. We tested these peptides in
elav; APP/BACE and elav;BACE/APP-Sw lines that display age-
progressive neurodegeneration and strong declines in cognitive
functions. Both COG112 and COG133 blocked neurodegenera-
tion and restored learning in the flies after abdominal injection or
oral administration after two injections before 7–8 days of age.
However, restoration of memory function was detected only in the
elav;APP/BACE line by 20–22 days of age and after 5 injections of
COG compounds.
Figure 5. ApoE-mimetics inhibit neurodegeneration in Dro-
sophila brain. A) Effect of peptides on percentage of the area lost in
the regions of the cell body and neuropil: The ratio of lost area was
calculated by dividing the sum of the vacuole areas from all brain
sections by the total area of the brain from all brain sections.
Percentage of the area lost is shown as averages6SEM. p,0.05
Asterisks indicate significant differences from control. B) Effect of
peptides on neurodegeneration in APP transgenic flies. Paraffin slices
were stained with hematoxylin and eosin and were examined under
bright-field illumination using a Leica DM 2500 microscope at a
magnification of 120X. Left panel- Bar, 50 mm; Right panels - Bar, 10 mm.
doi:10.1371/journal.pone.0008191.g005
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apoE-peptides, we analyzed their effect on Ab deposition in
transgenic flies. Expression of APP in the presence of BACE
caused significant accumulation of Ab in the cortical layer
containing neuronal cells, glial cells and small Ab deposits in the
neuropil of 10–15 day old flies (Fig. 6A). SH-8 significantly
decreased the size and density of Ab deposits (Fig. 6B) supporting
our previous observation that SH-8 inhibits amyloid growth [34].
Although some brain samples show decreased size of Ab deposits
after COG112 administration, the influence of this peptide on Ab
metabolism is difficult to interpret due to significant variations in
the sizes of detectable Ab deposits. Taking into consideration that
we found COG112 to partially suppress elevation of Ab 1–42
levels in mice after head injury [23], these results may only suggest
a slight effect of this peptide on Ab metabolism. In summary,
neuroprotective effects of apoE-mimetics in Drosophila probably
have multiple features that are not solely attributable to Ab-
mediated neurotoxicity.
Experiments describing restoration of cognitive functions in
transgenic animals demonstrate that protective effects may be
achieved at different levels. Administration of an ubiquitin C-
terminal hydrolase L1 (Uch-L1)—an enzyme associated with the
breakdown of excess or abnormal proteins, has a protective effect
on memory loss in a mouse model of AD (APP Sw-PS1M146V)
[51]. These authors showed that effect of the Uch-L1 is associated
with restoration of phosphorylation of the cAMP response element
binding protein (CREB). An increase in phospho-CREB levels
may stabilize synaptic connections and may contribute to long-
term memory formation.
Administration of the M1 muscarinic agonist, AF267B, can also
rescue selected deficits in Alzheimer’s models. The effect of
AF267B on cognition predicted changes in neuropathology that
were observed to be reductions in Ab and tau pathologies in the
hippocampus and cortex. The mechanism underlying this effect
on the Ab pathology was caused by the selective activation of
ADAM17 by AF267B treatment, thereby shifting APP processing
toward the non-amyloidogenic alpha-secretase pathway. Reduc-
tions in tau pathology appear to be mediated by decreased GSK3b
activity [52]. Finally, the ionophore 8-hydroxy-quinoline, which
targets metal-induced aggregation of Ab, significiantly decreased
soluble interstitial brain Ab within hours and improved cognitive
performance in APP transgenic mice [53].
The precise natures of neuroprotective functions of apoE
mimetics are not yet clear and several mechanisms have been
suggested. A recent report showed that the activity of apoE (133–
149) mimetic peptide depends on the low-density lipoprotein
receptor-related protein (LRP). Binding LRP by apoE(133–149)
results in inhibition of the N-methyl-D-aspartate (NMDA) receptor
Table 3. Effect of COG133 and COG112 on learning and memory in APP-nransgenic flies.
Genotype Peptide injection Learning Index (%) Memory Index (%)
7–8 days 21–22 days 7–8 days 21–22 days
elav;APP/BACE 2 petide 9.362.9 5.361.2 10.462.2 4.762.0
+Cog133 11.661.3 9.862.5 18.062.6 6.261.4
+Cog112 10.062.7 8.661.2 17.661.4 12.262.3
+Antp 6.061.1 6.261.3 6.162.7 3.661.5
elav;BACE;APPSw 2 petide 19.164.1 8.263.0 13.662.5 3.761.8
+Cog133 25.461.9 9.363.5 19.661.2 3.761.4
+Cog112 21.763.1 11.361.4 15.361.7 5.262.7
+Antp 28.766.5 10.761.7 10.462.1 4.061.1
The Learning Index and Memory Index were calculated as described in ‘‘Materials and Methods’’. All scores expressed as mean6SEM, (n=6) where (n) is a number of
independent assays. Statistical analysis was performed using one-way ANOVA and Tukey-Kramer multiple comparison post hoc test. Significance was accepted at
p,0.05. Groups of flies showing statistically significant recovery of learning and memory in comparison with control (Antp) are shown in bold font. 0.1 ml injections of
11.74 mM COG133, 11.47 mM COG112, and 11.71 mM Antp into the abdomen were performed every 4 days starting from day 2.
doi:10.1371/journal.pone.0008191.t003
Figure 6. Effect of peptides on Ab accumulation in Drosophila
brain. Immunohistochemistry with 4G8 antibody: A) Distribution of Ab
deposits in Drosophila brain, Bar, 50 mm. B) Effect of peptides on Ab
accumulation in Drosophila brain, Bar, 10 mm.
doi:10.1371/journal.pone.0008191.g006
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inhibitory potency of apoE(133–149) was threefold greater for
NMDAR transfected wild-type Chinese hamster ovary (CHO)
cells containing LRP compared with NMDAR-transfected CHO
cells deficient in LRP [54]. Another report shows that COG112
inhibits the inflammatory response to Citrobacter rodentium in colonic
epithelial cells by preventing NFkB activation [55]. This is an
important observation to help explain the effects of COG112 on
neurodegeneration in Drosophila because the TollRNFkB signaling
pathway mediates some neuropathological effects in Drosophila
[56].
In conclusion, our study suggests that multiple cellular
mechanisms are involved in restoring cognitive functions in APP
flies. This study with apoE-mimetics indicates that new approaches
to discover these mechanisms may lead to the development of new
therapeutics for the successful treatment of AD.
Materials and Methods
Lines of Drosophila and Maintenance Conditions
We used the following transgenic lines of D. melanogaster: UAS–
APP (carrying the human APP695), UAS–APP–Swedish (carrying
the human APP69 5 with the 670K3N, 671M3L mutations,
UASAPP DCT, UAS-APPDNT (truncated forms of APP695), elav–
GAL4c155, UAS–n-syb–eGFP (eGFPn- synaptobrevin), UAS-BACE
(carrying the human BACE). Expression of hAPP and its
truncated forms in neural cells of Drosophila was driven by the
tissue-specific transcription driver elav–GAL4c155.T h eU A S -
BACE was kindly provided by R. Reifegerste, the other stocks
were obtained from the collection of the Drosophila Bloomington
Stock Center. During the study, the flies were kept on the
standard yeast medium at a temperature of 29uC and a
photoperiod of 12 h.
Synaptobrevin expression was analyzed in the offspring of
crosses between elav–GAL4c155,UAS–n-syb-eGFP (aka. syb)f e -
m a l e sa n dm a l e sc a r r y i n gi n s e r t i o n so fAPP (APP–Swedish),
insertion of BACE and genes of truncated APP forms. Transgenic
lines were designated in text as following elav-GAL4c155;UAS-
APP (aka. elav;APP), elav-GAL4c155;UAS- APP/UAS-BACE (aka.
APP/BACE), elav GAL4c155;UAS-APP-Swedish (aka. elav;APP-Sw),
elav-GAL4c155; UAS-BACE; UAS- APP-Swedish (aka. BACE/
APP-Sw).
Western Blotting
Fly heads were homogenized in lysis solution containing 1x
PBS, 5 mM EDTA, 0.5% Triton X-100, and a complete protease-
inhibitor mix (Roche Applied Science, Mannheim, Germany).
Equal amounts of protein were separated by 10% SDS-PAGE,
transferred to Immobilon membranes (Millipore, Bedford, MA),
blocked in 5% low-fat milk for 2 hr at room temperature, and
incubated with the monoclonal antibody 22C11 (APP N terminal-
specific; Chemicon, Temecula, CA). Bound antibodies were
detected with goat anti-mouse peroxidase-conjugated secondary
antibody (Sigma, St. Louis, MO). For immunoprecipitation,
frozen pellets of fly heads were homogenized as described above,
and lysates were treated with protease and phosphatase inhibitors
(Sigma, St. Louis, MO). After pelleting insoluble material, the
lysate was incubated with anti-Ab monoclonal 4G8 (Signet
Laboratories, Dedham, MA) antibody (0.3 mg/ml of lysate) on
ice for 90 min, and then the antibody/antigen complexes were
recovered by incubation with protein G-Sepharose beads. After
pelleting and washing of the beads, recovered proteins were
fractionated by SDS/PAGE on 4–20% polyacrylamide Novex gels
(Wadsworth, OH ) and transferred to Immobilon membranes
(Millipore, Bedford, MA), blocked in 5% low-fat milk for 2 hr.
Bound antibodies were detected with goat anti-mouse peroxidase-
conjugated secondary antibody (Sigma, St. Louis, MO). All blots
were scanned and quantification of the relative intensity of each
band was evaluated by using the NIH Image J program (http://
rsb.info.nih.gov/ij/index.html). This method is outlined in the
Image J documentation: ‘‘Gel Analysis.’’
Table 4. Comparison of prevention of neurodegeneration in the brain of APP-transgenic flies by apoE-mimetics after injection and
feeding.
Genotype
Control (-peptide)
Degenerated area
Injection
Degenerated area
Feeding
Degenerated area
Cog133
elav; APP/BACE 20,060,8 11,761,2 9,560,6
elav; BACE; APP-Sw 18,362,0 8,760,6 8,661,3
Cog112
elav;APP/BACE 20,060,8 7,660,8 11,461,1
elav; BACE; APP-Sw 18,362,0 10,860,6 9,960,9
SH8
elav;APP/BACE 20,060,8 ND 13,461,3
elav; BACE; APP-Sw 18,362,0 ND 11,660,7
Ant
elav;APP/BACE 20,060.8 16,660,9 18,961,1
elav; BACE; APP-Sw 18,362,0 14,861,3 13,661,0
The degenerated area was calculated as described in Materials and Methods at day 30. Six brains were analyzed for each genotype. Statistical analysis was performed
using one-way ANOVA and Tukey-Kramer multiple comparison post hoc test. Significance was accepted at p,0.05. Results showing statistically significant decrease of
neurodegeneration in comparison with control are shown in bold font. Flies were cultured on standard fly food containing tested peptides, which were added every day
at concentrations of: 11.47 mM COG1112, 11.71 mM Antp, and 3.72 mM Antp-SH8.
0.1 ml injections of 11.74 mM COG133, 11.47 mM COG112, and 11.71 mM Antp into the abdomen where performed every 4 days starting from day 2. All scores expressed
as mean6SEM (n=6).
doi:10.1371/journal.pone.0008191.t004
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The flies were immersed in fixing solution (3.38 ml of 37%
formaldehyde (Merck), 0.5 ml of 1 M Na2PO4 (pH 6.8), 5 ml of
octane, and 1.12 ml of water) for 20 min. Fixed heads were
separated from the body in a phosphate buffer solution and put
into a second fixing solution (0.43 ml of 37% formaldehyde
(Merck), 0.4 ml of 1 M Na2PO4 (pH 6.8), and 3.17 ml of water)
for 90 min at 4uC. After fixation, the brains were isolated in a
phosphate buffer solution and placed on glass plates with hollows
containing a 1:1 mixture of phosphate buffer solution and glycerin.
Confocal Microscopy and Estimation of Fluorescence of
GFP–n-synaptobrevin
An LSM5 Pascal confocal microscope with a built-in 35-mW
argon laser was used for confocal microscopy. All samples were
scanned with the same scanning settings and the fluorescent signal
was visualized at l 488 nm. The slices for scanning were 2 mmi n
thickness. The resultant images and series of images were analyzed
using the LSM5 Image Browser software. The fluorescence
intensity was evaluated in microphotographs of confocal slices
using the Image J software (version 1.38a for Windows). (http://
rsb.info.nih.gov/ij/index.html). The methods of quantification are
outlined in the Image J documentation: ‘‘Image R Staks’’ and
‘‘Analyze RMeasure’’. Images of 2 mm optical sections were
converted to stacks, and regions containing mushroom bodies and
antennal lobes were demarcated using the ‘‘Freehand tool’’. Pixel
intensity in the selected areas was estimated using Image J
software. For calculation of relative intensities the pixel intensity
was normalized to the fluorescent signal of elav genotype. Four
brains were analyzed for each genotype. Related intensities are
shown in means6SEM. Statistical analysis was performed using
one-way ANOVA and Tukey-Kramer multiple comparison post
hoc test. Significance was accepted at p,0.05
Peptides, Abdominal Injections, Oral Administrations
Peptides used for studies included Penetratin (Antp 43–58) -
RQIKIWFQNRRMKWKK; CF (fragment 142–153 of human
growth factor U2AF)-SQMTRQARRLYV, Antp-COG133 (CO-
G112)-RQIKIWFQNRRMKWKKCLRVRLASHLRKLRKRL-
L, COG133-LRVRLASHLRKLRKRLL, SH8 – RHVLPK-
VQA. Antp-SH8: RQIKIWFQNRRMKWKK-RHVLPKVQA.
An N-terminal tag of biotin-cAbu (gamma-aminobutyric acid) was
added to penetratin (Antp), COG133, Antp-COG133 (COG112),
CF (U2AF, 142–153). Untagged peptides COG133, Antp-
COG133 and SH8 were synthesized by the solid phase technique
on an ABI Model 430A synthesizer. Peptides were then
deprotected by treatment with anhydrous hydrogen fluoride in
presence of m-cresol and purified by preparative reverse-phase
chromatography. Purified peptides were characterized by analyt-
ical RP-HPLC using a DeltaPak C-18 column with a 20–50%
gradient of acetonitrile in 0.1% trifluoroacetic acid at 1 ml/min.
Amino acid analysis was performed following complete hydrolysis
in 6N HCl for 24 hr at 110uC (LKB 4151 Alpha Plus amino acid
analyzer, Sweden) and mass-spectrum analysis was performed on a
Voyager-DE BioSpectrometry Workstation (PerSepetive Biosys-
tems, USA). Purity of all peptides used in this study was .95%.
Abdominal injections were performed as we described in [56].
After dissolving peptides in Ringer’ solution (7.5 g/liter NaCl/
0.35 g/liter KCl/0.2g/liter CaCL2; pH 7.6–7.8), they were
injected in a volume of 0.2 ml per fly into the abdomen using
glass pipettes (20–40 mm tip diameter) coupled to an injector and
micromanipulator. Peptides were injected on days 2, 5, 9, 13, 17,
21, 25 and 29 post-eclosion. For oral administration, tested
peptides were added every day to standard fly food at final
concentrations of 11.47 mM COG133 and COG 112, 11.71 mM
Antp, 3.72 mM Antp-SH8.
Immunohistochemistry
For immunostaining flies were fixed in freshly prepared
Carnoy’s fixative for 24 hours. Next, flies were dehydrated
sequentially in 30, 50, 75, and 100% ethanol and embedded in
paraffin. 6 mm thick sections were blocked for 1 hr in 0.5% nonfat
dry milk, 0.1% Tween-20 in PBS, washed two times with 0.1%
Tween-20 in PBS and two times with PBS. Slides were then
incubated with anti-Ab monoclonal 4G8 (Signet Laboratories,
Dedham, MA) (1:500) (or antibody to biotin- Sigma, St.Louis,
MO) for 2 hours, washed four times with PBS and incubated with
goat anti-mouse phosphatase-conjugated secondary antibody
(Sigma, St. Louis, MO) for 2 hours. Slides were washed with
PBS. Nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-
indolyl phosphate substrate (1-STEP NBT/BCIP, Pierce) was
added to slides until desired stain intensity develops. Finally, slides
were rinsed with water.
Neurodegeneration Assay
The fly heads were fixed in freshly made Carnoy’s fixative for
24 h at a temperature of 4uC, embedded in paraffin, and 5 mm
paraffin slices were prepared as described [25]. Paraffin slices were
stained with hematoxylin and eosin (Bio Optica, Italy). Next, slices
were examined under bright-field illumination using a Leica DM
2500 microscope at magnification of 120X. To quantify
neurodegeneration in the cell body and neuropil, images of the
5 mm brain sections stained with hematoxylin and eosin and were
captured using bright-field microscopy. The areas of the vacuoles
in the cell body and neuropil regions on each brain section were
measured using NIH Image J software (http://rsb.info.nih.gov/ij/
index.html). The method of quantification is outlined in the Image
J documentation: ‘‘Particle Analysis.’’ The ratio of lost area was
calculated by dividing the sum of the vacuole areas from all
sections by the total area of the brain from all sections. Percentage
of the area lost is shown as average6SEM. We analyzed 6 brains
for each genotype, 16–18 sections per brain. Statistical analysis
was performed using one-way ANOVA and Tukey-Kramer
multiple comparison post hoc test. Significance was accepted at
p,0.05
Olfactory Associative Learning
Olfactory associative learning was performed as described on
50 to 100 flies per group [30]. Flies were trained by exposure to
electroshock paired with one odor: octanol or methylcyclohex-
anol, for 60 s and subsequent exposure to the other odor without
electroshock for 60 s. Immediately after training, learning is
measured by allowing flies to choose between the two odors for
120 s (Learning Index) or after 1.5 hour (Memory index).
Performing index (P.I.) (Learning Index or Memory Index) was
calculated as the number of flies that responded correctly (to
avoid the shock-paired octanol) minus the number of flies that
responded incorrectly (to avoid the control odor methylcyclohex-
anol) divided by the total number of flies. To eliminate naive odor
bias, each trial was composed of two half-trials, where one group
was trained to associate octanol with shock and the other to
associate methylcyclohexanol with shock, and the complete P.I.
was the average of these two half-trial P.I.s. Statistical analysis
was performed using one-way ANOVA and Tukey-Kramer
multiple comparison post hoc test. Significance was accepted at
p,0.05.
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Statistical analyses were performed using the KyPlot software
(KyensLab Inc). One-way ANOVA was followed by planned
multiple comparisons between relevant groups with Tukey-
Kramer test.
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